Skip to main content
Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc. — Investor Relations & Filings

Ticker · LYRA ISIN · US55234L1052 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2021-11-09 Earnings Release
Country US United States of America
Listing US LYRA

About Lyra Therapeutics, Inc.

https://lyratherapeutics.com/

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company that develops and commercializes innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). The company's product candidates are long-acting, anti-inflammatory sinonasal implants designed to deliver medication directly to sinonasal tissues. This approach aims to provide a new, long-lasting treatment option for patients with this debilitating inflammatory disease, targeting tissues that are not easily accessible with conventional therapeutic methods.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2021, reporting the company's financial results for the quarter ended September 30, 2021. It includes a press release as Exhibit 99.1 announcing the quarterly financial results. The text explicitly states it is a Current Report on Form 8-K and the content is a financial results announcement for a quarter, which aligns with an Earnings Release (ER). The document length is 3549 characters, which is typical for an 8-K earnings release filing. There is no detailed financial statement or comprehensive analysis, just the announcement of quarterly results. Therefore, the correct classification is Earnings Release (ER).
2021-11-09 English
FORM 4 SUBMISSION
Director's Dealing
2021-09-15 English
FORM 3 SUBMISSION
Director's Dealing
2021-09-15 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 12, 2021, reporting the appointment of a new Chief Financial Officer and related management changes at Lyra Therapeutics, Inc. The content focuses on the departure and appointment of directors and officers, employment agreements, and related compensatory arrangements. There are no financial statements or detailed financial performance data presented. The primary subject is changes in senior management and board-related information. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under the category 'Board/Management Information' (MANG). Therefore, this document is best classified as MANG with high confidence.
2021-09-15 English
10-Q
Interim / Quarterly Report Q2 2021
2021-08-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 9, 2021. It announces the company's financial results for the quarter ended June 30, 2021, and includes a press release as an exhibit. The text explicitly states that the press release is furnished and not filed, and the document is relatively short (3612 characters). The content is an initial announcement of quarterly financial results, which aligns with the definition of an Earnings Release (ER). It is not a full quarterly report or detailed financial statements, but a press release announcing results. Therefore, the correct classification is Earnings Release (ER).
2021-08-09 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.